The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear…

Bridge Consulting examines the opportunities and challenges ahead for China's mRNA vaccine industry in the post-COVID era. Having eschewed…

The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT…

Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a…

The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the…

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…